AC Immune to Participate in Two Investor Conferences and Provide Scientific Updates at AAT-AD/PD Conference

Lausanne, Switzerland, - February 6, 2018 -   AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced that it will participate in two investor conferences in February 2018. CEO, Prof. Andrea Pfeifer will present at the Leerink Partners Annual Global Healthcare conference in New York and the Company will participate in the Credit Suisse Global Healthcare Conference in London

AC Immune and its collaborators will also provide five updates on the advancement of its partnered and wholly-owned product candidates and technology platform at the AAT-AD/PD^TM Focus Meeting 2018 in Torino, Italy, on 15-18 March 2018. The updates will cover the alpha-synuclein PET tracers, the vaccine technology of AC Immune, the anti-amyloid-ß monoclonal IgG4 antibody crenezumab, partnered with Genentech (a member of the Roche group), and the Tau-PET imaging agent, partnered with Piramal Imaging. Additionally, Dr. Andreas Muhs, CSO of AC Immune will participate in a panel addressing translational research in drug discovery for Alzheimer's disease.

Investor Presentations
Leerink Partners Annual Global Healthcare Conference, New York, US
February 14-15, 2018
Date: February 15, 2018 | 10:30 am ET
Venue: Lotte New York Palace
Presenter: Prof. Andrea Pfeifer, CEO, AC Immune
A webcast of the presentation will be available on the Investor Page of AC Immune's website and will be active for 90 days following the event.

Credit Suisse 2018 Global Healthcare Conference, London, UK - February 27-28, 2018
CEO, Prof. Andrea Pfeifer and CFO, Joerg Hornstein will be available on both days for 1x1 meetings with investors.
Venue: Credit Suisse Offices, 5 Canada Square, London

Scientific updates at the AAT-AD/PD^TM conference, Torino, Italy - March 15-18, 2018
Alpha-synuclein-PET imaging agent

• Novel alpha-synuclein positron emission tomography (PET) tracers for the diagnosis of Parkinson's disease
  Date: March 15, 2018 | 3:40 - 4:40 pm CET
  Presenter: Oral presentation by Francesca Capotosti, PhD - AC Immune

SupraAntigen vaccine technology

• Development of highly sensitive MSD assays for the detection of anti-Abeta antibodies specific for pathological Abeta species and for Abeta peptide present on the liposomal vaccine
  Date: March 17, 2018 | 8:00am - 6:00pm CET
  Presenter: Poster presentation by Emma Fiorini, PhD - AC Immune

Crenezumab

• Safety, tolerability and pharmacokinetics of crenezumab in mild-to-moderate AD patients treated with escalating doses for up to 32.3 months
  Date: March 15, 2018 | 8.00am - 6.00pm CET
  Presenter: Poster presentation by Helen Lin, PhD - Genentech

Tau-PET imaging agent

• PI-2620, Clinical evaluation of a next generation Tau-PET agent in subjects with Alzheimer's disease and progressive supranuclear palsy
  Venue: SALA 500
  Date: March 15, 2018 | 11:40 am - 12:00 CET
  Presenter: Oral presentation by Andrew Stephens, MD, PhD - Piramal Imaging

Forum discussion

• Translational Research in Drug Discovery for Alzheimer's Disease
  Venue: SALA 500
  Date: March 15, 2018 | 3:40pm - 4:40pm CET
  Dr. Andreas Muhs, CSO of AC Immune will participate in a forum discussion moderated by Dr. Jeffery Cummings and Ezio Giacobini.

About AC Immune
AC Immune is a clinical stage Swiss-based biopharmaceutical company focused on neurodegenerative diseases with four product candidates in clinical trials. The Company designs, discovers and develops therapeutic and diagnostic products intended to prevent and modify diseases caused by misfolding proteins. AC Immune's two proprietary technology platforms create antibodies, small molecules and vaccines designed to address a broad spectrum of neurodegenerative indications, such as Alzheimer's disease (AD). The Company's pipeline features nine therapeutic and three diagnostic product candidates. The most advanced of these is crenezumab, a humanized anti-amyloid-ß monoclonal IgG4 antibody that targets monomeric and aggregated forms of amyloid-ß, with highest affinity for neurotoxic oligomers currently in Phase 3 clinical studies for AD. This global program is being conducted by the collaboration partner Genentech (a member of the Roche group). Other collaborations include Biogen, Janssen Pharmaceuticals, Nestlé Institute of Health Sciences, Piramal Imaging and Essex Bio-Technology.

Forward looking statements
This press release contains statements that constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immune's strategies or expectations. In some cases, you can identify these statements by forward-looking words such as "may," "might," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "projects," "potential," "outlook" or "continue," and other comparable terminology. Forward-looking statements are based on management's current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions "Item 3. Key Information-Risk Factors" and "Item 5. Operating and Financial Review and Prospects" in AC Immune's Annual Report on Form 20-F and other filings with the Securities and Exchange Commission.  Forward-looking statements speak only as of the date they are made, and AC Immune does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.

For further information, please contact:

Attachments:

http://www.globenewswire.com/NewsRoom/AttachmentNg/b250cb30-e609-46e2-9927-e6ff0756899e